Latest Advances in Lung Cancer Research

A study of over 10,000 people showed that sticking with regular lung cancer screening leads to better detection of early-stage cancer. However, fewer people returned for follow-up screenings each year.

Researchers at Johns Hopkins Medicine have developed an innovative computer model that could significantly improve immunotherapy outcomes for lung cancer patients.

A new JAMA review shows that small cell lung cancer, which affects 95% smokers and has only 12-30% five-year survival, is seeing breakthrough improvements with immunotherapy extending survival to 56 months for early-stage disease, though advanced cases remain challenging with most patients relapsing within three months.

The study highlights that the timing of irAEs depends on the specific immunotherapy and recent treatment history.

New research separates the effects of smoking, environment, genetics, and healthcare access on lung cancer mortality, providing insights for better prevention strategies.

Phase III trial shows mobocertinib performs similarly to chemotherapy for EGFR exon 20 insertion lung cancer patients.

Early detection of incidental lung nodules can lead to timely treatment and improved survival rates for lung cancer patients.

New hope for small cell lung cancer patients as the first patient receives Peluntamig in a clinical trial. This experimental drug targets specific cancer growth pathways.

New blood test using ctDNA methylation biomarkers shows promise for early lung cancer detection, potentially improving treatment outcomes for patients.

New drug shrinks HER2-mutant lung cancer tumors in 73% of patients, offering hope for improved treatment options.

Comprehensive review examining molecular mechanisms of cancer invasion and metastasis, identifying potential therapeutic targets for preventing cancer spread.

Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.